The global personalized medicine market size was valued at approximately USD 529.31 billion in 2023. It is expected to reach around USD 1,168.39 billion by 2033, expanding at a compound annual growth rate (CAGR) of 8.24% from 2024 to 2033.
The personalized medicine market is driven by the growing advancement in genomic technologies, increasing prevalence of chronic disease, rising government initiatives and funding, and increasing investment by the pharmaceutical industry and others.
The goal of personalized medicine is to provide more individualized and focused therapies by utilizing each patient’s unique genetic composition, lifestyle, and medical background. Personalized medicine is the use of sophisticated diagnostic tests and instruments by medical professionals to pinpoint genetic variants or other biomarkers associated with particular illnesses. Through analysis of this data, the medical professional may create individualized treatment regimens that are suited to the unique requirements of each patient. Furthermore, personalized medicine is a fast-developing discipline with the potential to change healthcare by lowering costs, increasing patient outcomes, and enhancing the precision and efficacy of medical therapies.
- The most recent estimates from the Personalized Medicine Coalition state that over 75,000 genetic testing kits and 300 personalized medications are available for use by patients with various chronic and infectious illnesses, uncommon genetic disorders, and cancers.
Key Insights:
- North America dominated the global market in 2023, holding a significant 41% share.
- Asia Pacific’s personalized medicine market is forecasted to expand at the most rapid pace from 2024 to 2033.
- Personalized nutrition and wellness products accounted for a substantial 33% of the market revenue in 2023.
- Personalized medicine therapeutics are projected to witness the most significant growth in market share from 2024 to 2033.
- Hospitals remained the primary end-user of personalized medicine, driving the largest portion of market revenue in 2023.
Get Sample@ https://www.visionresearchreports.com/report/sample/37100
Personalized Medicine Market Dynamics:
Drivers: Increasing prevalence of rare disease
The rising prevalence of rare diseases is also expected to drive the personalized medicine market’s expansion. The increased understanding and association of human genetic traits has opened the path for efforts to develop diverse personalized medicine and therapeutic interventions.
For example, in September 2022, a research study conducted at the University of California, Irvine, offered a revolutionary strategy for managing inherited retinal disorders (IRDs) by precision genome editing that is highly tailored to each individual’s needs.
Restraint: High development cost and reimbursement challenges
It can be costly to undertake in-depth genetic testing and develop tailored medicines. For many individuals and healthcare systems, personalized medicine may not be as accessible due to the high expenses of research, development, and implementation. Furthermore, the establishment of personalized medicine reimbursement models poses significant problems, and the lack of clarity surrounding compensation may impede the broader implementation of these treatments.
Opportunity: Growing partnership for personalized medicine research across regions
The growing partnership for personalized medicine research across the region is expected to offer a lucrative opportunity for the personalized medicine market’s development during the forecast period. For instance, in October 2023, at a high-level meeting on personalized medicine held in Valencia on October 5, 2023, the new European Partnership for Personalized Medicine (EP PerMed) was formally introduced.
The conference, held under the auspices of the Spanish Presidency of the Council of the European Union, centered on the impact of personalized medicine on the advancement of healthcare and its potential to enhance the quality of life for individuals. With 49 partners involved in its creation, the Partnership kick-off represents a boost to precision medicine research throughout the European Research Area. Precision medicine will benefit from its promotion across all fields and specialties, as well as from its facilitation of innovation and transfer, consolidation in health systems, and potential for ongoing development.
Personalized Medicine Market by Segmental Analysis
Product Insights
In 2023, the personalized nutrition and wellness segment captured a dominant 33% share of total revenue, fueled by high consumption rates and extensive market penetration. This segment benefits significantly from the widespread use of over-the-counter (OTC) nutrition products, which face fewer regulatory barriers. A notable example is Viome Life Sciences’ acquisition of Naring Health, along with its DiscernDX platform, in November 2023. DiscernDX is renowned for its capabilities in regular health monitoring, early disease detection, and personalized care. This acquisition enhances Viome’s position in the personalized health solutions sector by improving its ability to provide precise dietary and supplement recommendations. This strategic move represents a significant step forward in personalized nutrition, offering customers in-depth health insights and tailored strategies to address their specific health concerns.
The personalized medicine therapeutics segment is projected to experience the highest compound annual growth rate (CAGR) from 2024 to 2033. A key factor driving this growth is the advancement in next-generation sequencing technology. The development of high-capacity, rapid sequencing platforms is anticipated to dramatically reduce the cost of sequencing the entire human genome, leading to broader adoption and use of precision medical therapies.
End-Use Insights
In 2023, the hospital sector led the personalized medicine market with the highest revenue share. Hospitals play a pivotal role in this market, both as primary end-users and influential stakeholders. There is an increasing trend toward incorporating genomic diagnostics and targeted therapies within hospital settings, highlighting a growing focus on personalized medicine. Hospitals are increasingly utilizing genetic information to tailor treatments to individual patients, thereby driving advancements in diagnostic tools and therapeutic methods. By embracing genomics, hospitals not only contribute to the growth of the personalized medicine market but also promote innovation, improve patient outcomes, and lead the way in transformative healthcare practice.
Regional Analysis of the Personalized Medicine Market:
1. North America
- Market Share (2023): North America accounted for the largest share of the personalized medicine market, holding 41%.
- Growth Drivers: The dominance in this region is attributed to strong support from research institutions and major pharmaceutical companies. Personalized medicine is increasingly utilized in treating various diseases and in drug discovery processes. Significant advancements in precision diagnostics, like Illumina, Inc.’s TruSight Oncology 500 (TSO 500) assay, which can identify up to 523 cancer biomarkers, are also driving market growth.
- Key Trends: Ongoing innovation in precision diagnostics and a high adoption rate of personalized therapies will likely sustain North America’s market leadership.
2. Europe
- Projected Growth: The personalized medicine market in Europe is expected to grow at a robust CAGR from 2024 to 2033.
- Growth Drivers: Developments in countries like Germany, the UK, and France are expected to propel market growth. These regions are focusing on integrating personalized medicine into their healthcare systems, supported by government initiatives and increasing investment in R&D.
- Key Trends: Strategic collaborations, government support, and the establishment of regulatory frameworks for personalized treatments are expected to create lucrative opportunities in Europe.
3. Asia-Pacific
- Expected Growth: The Asia Pacific personalized medicine market is anticipated to experience the fastest CAGR from 2024 to 2033.
- Growth Drivers: Key factors driving this rapid growth include expanding healthcare infrastructure, increasing healthcare expenditures, and the entrance of major players into the market. Collaborations, like the one between MGI and MiRXES in June 2022 to enhance access to advanced spatial multiomics research, are expected to broaden market reach and impact.
- Key Trends: Rising awareness of personalized healthcare, significant investments in genomics, and expansion strategies by international players will fuel market growth.
4. Latin America
- Growth Projections: The market in Latin America continues to grow steadily, driven by enhancements in healthcare infrastructure and increasing awareness of personalized therapies.
- Key Trends: Investments by pharmaceutical companies and increased government initiatives to promote healthcare quality are expected to sustain market growth.
5. Middle East and Africa (MEA)
- Growth Projections: The MEA market, while smaller, shows growth potential, driven by government initiatives to improve healthcare standards and investments in genomic research.
- Key Trends: Establishment of research centers focused on genetic disorders and personalized medicine will likely boost market growth in the coming years.
Recent Market News
- In September 2023, Agilent Technologies and the Advanced Cell Therapy and Research Institute Singapore (ACTRIS) signed a Memorandum of Understanding (MOU) to collaborate on advancing gene and cell therapy over the next three years.
- In July 2023, Illumina and Pillar Biosciences entered a strategic partnership to expand Illumina’s oncology product portfolio by commercializing Pillar’s range of oncology assays on a global scale. This agreement aims to enhance the availability of additional Next-Generation Sequencing (NGS) solutions, thereby improving patient access to personalized cancer treatment options.
- In June 2023, GE Healthcare and DePuy Synthes finalized a distribution agreement to broaden the availability of the OEC 3D Imaging System and extend DePuy Synthes’ product offerings to a wider network of surgeons and patients across the United States.
- In June 2023, Exact Sciences Corp. formed independent collaborations with two leading healthcare institutions renowned for cancer research. These partnerships are focused on increasing access to genomic information to enhance patient care and improve cancer treatment outcomes.
Read More@ https://www.heathcareinsights.com/epigenetics-market/
Top Manufactures in Personalized Medicine Market
- GE Healthcare
- Illumina, Inc.
- ASURAGEN, INC.
- Abbott
- Dako A/S
- Exact Sciences Corporation
- Danaher Corporation (Cepheid, Inc.)
- Decode Genetics, Inc.
- QIAGEN
- Exagen Inc.
- Precision Biologics
- Celera Diagnostics LLC.
- Biogen
- Genelex
- International Business Machines Corporation (IBM)
- Genentech, Inc.
- 23andMe, Inc.
Personalized Medicine Market Segmentation:
By Product
- Personalized Medicine Diagnostics
- Genetic Testing
- Direct-To-Consumer (DTC) Diagnostics
- Esoteric Lab Services
- Esoteric Lab Tests
- Personalized Medicine Therapeutics
- Pharmaceutical
- Genomic Medicine
- Medical Devices
- Personalized Medical Care
- Telemedicine
- Health Information Technology
- Personalized Nutrition & Wellness
- Retail Nutrition
- Complementary & Alternative Medicine
By End-use
- Hospitals
- Diagnostic Centers
- Research & Academic Institutes
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/37100
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308